# Page 1
On administrative approval as a special case for the purchase of medicines procured in the second wave of COVID-19.
The Government of Maharashtra
the Department of Public Health
Government Resolution No: PRASHAMA-1221/ PR No.29/ HEALTH-7
10th Floor, Hospital Building
New Ministry, Mumbai- 400001.
Date: July 20, 2021.
Read: 1) Commissioner, Director of Health Services and Mission Director, National Health Mission, Mumbai vide letter No.
dated 30.06.2021 2) Ma. Decisions taken in the meeting of Empowered High Powered Committee held on 08.07.2021 under the Chairmanship of Chief Secretary. (Department of Industry, Energy and Labor No. Bhankhas 2021/ Q.No.97/ Industry-4, dated 09.07.2021.)
Preamble: A proposal was under consideration of the Government to grant administrative approval as a" special case" to the purchase of medicines procured in the emergency situation during the ongoing second wave of COVID-19.
GOVERNMENT DECISIONS: The revised Manual of Procedure for procurement of offices by Government Departments has been published under the Government Decision, Industries, Energy and Labour Department, dated 01.12.2016. Purchase Policy as per Government Decision, Industries, Energy and Labour Department, dated 23.04.2021 and PDF dated 04.05.2021, as per the above mentioned policy, vide para. 3.3.1.2 has been added. These include emergency works to prevent the spread of the Covid-19 pandemic, facilities to be provided to the affected patients, and for the emergency purchase of medicines and other materials. A high-powered committee has been constituted under the chairmanship of the Chief Secretary.
In the meeting of the Empowered High Powered Committee held on 08.07.2021, the Centre decided to procure the medicines procured in the second wave of COVID-19 in emergency situations at the level of Commissionerate of Health Services and May Haffkine Biopharma Corporation.
# Page 2
Government Resolution No: PRASHAMA-1221/ PR No.29/ HEALTH-7
Subject to the condition that the quantity received as per the government quota and as well as the express interest and the price paid by the manufacturers/ suppliers is within the limit of the rate fixed by the National Pharmaceuticals Pricing Authority (NPPA), it has been decided to exempt from certain provisions of the Purchase Policy 2016 and post-supply drug testing in order to avoid the loss of patients by prompt treatment.
In pursuance of the decision taken by the Empowered High-Powered Committee in its meeting held on 08.07.2021, the following drug purchases made during the second wave of COVID-19 are being accorded administrative approval:
-----------------------------------------------------------------------------------------------------------------------------
| A.A.       | The name of the medicine | the number of supplies | The process of purchasing | Total cost of purchase (Rs.) |
| 1          | Inj.Remdesivir           | 3,67,094               | GOI allocation/ Eol       | 66,01,42, 975/               |
| 2          | Inj.Amphotericin B       | 4,64,700               | GOI allocation / EoI      | 92,20,14, 966/               |
| 3          | Posaconazole             | 500                    | GOI allocation/ Eol       | 56,70,000/                   |
| 4          | Inj. Tocillizumab        | 410                    | GOI allocation/Eol        | 1,39,22, 136/                |
| the total. | 160,17,50, 077/          |
-----------------------------------------------------------------------------------------------------------------------------
In view of the approval of the Empowered High Powered Committee, the administrative approval for the purchase of the above drugs is being granted subject to the following terms and conditions: 1. The number and manufacturers received as per the quota and express interest of the Central Government at the level of the Commissionerate of Health Services and May Haffkine Biopharma Corporation.
The price should be within the prescribed limit of the National Pharmaceutical Pricing Authority (NPPA).
2. In order to avoid casualties by providing immediate treatment, the use of medicines is being allowed by exempting them from post-supply drug testing.
(iii) Purchase of the same drug at different prices by the suppliers is being allowed within the limits of the rates fixed by the National Pharmaceuticals Pricing Authority (NPPA).
4. Expenditure on the subject ECRP under COVID-19 PIP for FY 2021-22
Funds should be provided from the available grants. The procurement should be completed within the stipulated period of administrative approval.
Page 2 of 4
# Page 3
Government Resolution No: PRASHAMA-1221/ PR No.29/ HEALTH-7
Storage and distribution of the items to be procured after supply, supply chain management and inventory management should be done in a proper manner to ensure that these items do not remain unused and are used in a timely manner.
The Commissioner (Health Services) and Mission Director, National Health Mission, Mumbai, Director (Health Services), Directorate of Health Services, Mumbai, Joint Director, Health Services (Procurement Cell), Directorate of Health Services, Mumbai and the Programme Head shall be solely responsible for ensuring that the procurement is as per the norms and requirements.
Government Resolution, Department of Finance, vide No. 2013/ Q. No. 30/13/ Regulations, Part-II, dated 17th April, 2015, in the Financial Powers Rules, 1978, Part-I, Sub-Section-II, Section 4, Rule No. Under Section 7, the administrative department has been given full powers to approve the purchase of implements, spare parts and activity kits.
# Page 4